Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Wave Life Sciences Ltd. (WVE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.4500-0.2100 (-5.74%)
At close: 04:00PM EST
3.4500 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.6600
Open3.6700
Bid3.3300 x 1800
Ask3.5200 x 900
Day's Range3.3500 - 3.7200
52 Week Range3.3500 - 12.1700
Volume214,036
Avg. Volume480,741
Market Cap172.008M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-3.3780
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.86
  • Zacks

    Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates

    Wave Life Sciences (WVE) delivered earnings and revenue surprises of 81.25% and 240.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

    Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly specific RNA editing and restoration of functional AAT protein substantially above therapeutic threshold; potential for best-in-class, potent and durable RNA editing in vivo in multiple preclinical models and tissues Dosing ongoing in three clinical programs (WVE-004, WVE-003, WVE-N531); data being ge

  • GlobeNewswire

    Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference

    CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 10:00 a.m. ET. A live webcast of the presentation wil

Advertisement
Advertisement